First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared with treatment with dacarbazine. Toripalimab blocks the PD-1 receptor on T-cells, allowing the immune system to better attack cancer cells. The study compared toripalimab as first-line treatment with dacarbazine chemotherapy in patients with advanced acral melanoma. The main finding was a statistically significant prolongation of PFS in the toripalimabor arm compared to the control group. Toripalimab has been approved for other indications such as nasopharyngeal carcinoma, where it improved PFS and OS in clinical trials such as JUPITER-02. In melanoma, it was initially approved in China in 2018 for unresectable or metastatic disease. The study highlights the importance of toripalimab in the treatment of advanced forms of melanoma.